A progressive decline in memory and thinking caused by Alzheimer's disease, ranging from mild, early changes to major, disabling impairment.
Medically reviewed by
Dr. Mihaela G.
Neurocognitive Disorder due to Alzheimer’s Disease describes a progressive decline in memory and other cognitive abilities caused by the specific, identifiable brain changes of Alzheimer’s disease, the most common underlying cause of major cognitive decline in older adults. DSM-5-TR distinguishes Mild Neurocognitive Disorder, noticeable cognitive decline that doesn’t yet significantly interfere with independent daily functioning, from Major Neurocognitive Disorder, decline severe enough to require assistance with everyday activities, recognizing that Alzheimer’s disease typically progresses gradually along this continuum rather than appearing suddenly at a severe stage.
The hallmark, earliest feature is almost always a distinctive pattern of memory impairment, specifically difficulty learning and retaining new information, while memories from further in the past often remain relatively well-preserved considerably longer. This pattern, new information not “sticking” while older memories persist, is one of the more clinically distinctive and recognizable early signs, though it’s frequently misattributed, by patients and families alike, to ordinary aging or stress before the underlying cause becomes clear.
A genuinely important point for both patients and families involves the distinction between Mild NCD and normal age-related cognitive change. Some decline in processing speed and word-finding is a typical, expected part of aging and isn’t, by itself, cause for concern. Mild NCD due to Alzheimer’s involves a more specific, measurable decline from a person’s own previous baseline, generally still preserving independence, but representing genuine, identifiable change rather than normal variation.
Distinctive memory impairment
A hallmark, early pattern of difficulty learning and retaining new information, while memory for events from the more distant past typically remains relatively preserved for considerably longer, especially in early stages.
Mild Neurocognitive Disorder presentation
In the mild stage, noticeable decline in memory or another cognitive domain that represents a genuine change from prior functioning, but doesn’t yet significantly interfere with the capacity for independent daily activities, though some additional effort, compensatory strategies, or accommodation may be needed.
Major Neurocognitive Disorder presentation
In the major stage, cognitive decline severe enough to interfere with independence in everyday activities, requiring assistance with tasks such as managing finances, taking medications correctly, or, eventually, basic self-care.
Additional cognitive domains affected
As the condition progresses, additional impairment typically develops in language (word-finding difficulty, eventually more significant language breakdown), executive function (planning, organizing, problem-solving), and visuospatial ability (getting lost in familiar places, difficulty with spatial tasks).
Behavioral and psychological symptoms
Many people develop behavioral or psychological symptoms over the course of the illness, including apathy, irritability, anxiety, depression, and, in later stages, agitation or psychotic symptoms, captured by the diagnostic specifier “with or without behavioral disturbance.”
⋅ Anxiety or distress connected to awareness of cognitive changes, particularly in earlier stages
⋅ Depression, common throughout the course of the illness
⋅ Apathy and reduced emotional engagement, often increasing as the illness progresses
⋅ Irritability or agitation, particularly as the condition advances
⋅ Difficulty learning and retaining new information, with relatively preserved distant memory early on
⋅ Word-finding difficulty and progressive language impairment
⋅ Impaired planning, organizing, and problem-solving (executive function)
⋅ Disorientation to time and place, and difficulty with spatial tasks, including getting lost in familiar locations
⋅ No specific physical symptoms in earlier stages beyond cognitive changes
⋅ Progressive difficulty with coordinated movement in later stages of major NCD
⋅ Eventually, difficulty with basic physical self-care tasks in advanced major NCD
⋅ Sleep disturbance, common throughout the course of the illness
⋅ Increasing reliance on notes, reminders, or others to compensate for memory difficulty
⋅ Withdrawal from previously enjoyed activities, particularly as apathy develops
⋅ Repetitive questions or statements connected to memory impairment
⋅ Agitation or wandering behavior, particularly in later, major stages
Approximately 6-7% of adults over 65 have Alzheimer’s-related Major Neurocognitive Disorder, with prevalence rising sharply with age, and Alzheimer’s disease represents the most common identifiable cause of major cognitive decline among older adults overall.
Risk factors include older age (by far the strongest risk factor), a family history of Alzheimer’s disease, the APOE-e4 genetic variant (which increases risk without guaranteeing the condition will develop), cardiovascular risk factors (including high blood pressure, diabetes, and high cholesterol), and lower levels of education and cognitive engagement across the lifespan, which some research suggests may relate to differences in “cognitive reserve.”
Comorbidity with depression and anxiety, particularly in earlier stages when awareness of cognitive change is often preserved, is substantial, and mixed presentations involving both Alzheimer’s disease and vascular contributions to cognitive decline are increasingly recognized as common, rather than representing entirely separate, mutually exclusive categories.
Alzheimer’s disease involves specific, identifiable changes in brain structure and function, accumulating gradually, often beginning years before symptoms become noticeable.
Amyloid plaques and neurofibrillary tangles, abnormal protein accumulations in and around brain cells, are the defining pathological features of Alzheimer’s disease, disrupting normal cell function and communication, and ultimately contributing to progressive neuronal loss, particularly in brain regions critical for memory.
Genetic factors contribute meaningfully to risk; the APOE-e4 variant is the most significant genetic risk factor for the more common, later-onset form of the disease, while rare, specific genetic mutations are responsible for a small proportion of cases, particularly those with notably early onset (sometimes before age 65).
Cardiovascular health is increasingly recognized as significantly connected to Alzheimer’s risk; conditions affecting blood flow and vascular health, including high blood pressure, diabetes, and high cholesterol, are associated with increased risk, suggesting genuine overlap between vascular health and the underlying disease process, beyond what might be expected from coincidental co-occurrence alone.
Cognitive and social engagement across the lifespan appears to relate to risk as well, with higher education and ongoing cognitive engagement associated with somewhat reduced risk, though the exact mechanism, whether reflecting genuine protective effects or simply a greater “cognitive reserve” that delays when symptoms become apparent for a given level of underlying pathology, remains an active area of research.
Mild Neurocognitive Disorder due to Alzheimer’s Disease is diagnosed when there’s evidence of modest cognitive decline from a previous level of performance in one or more cognitive domains, based on concern from the individual, a knowledgeable informant, or the clinician, alongside objective evidence of impairment, but the deficits don’t interfere with capacity for independence in everyday activities, though greater effort or compensatory strategies may be required.
Major Neurocognitive Disorder is diagnosed when there’s evidence of significant cognitive decline, with deficits sufficient to interfere with independence in everyday activities, requiring assistance with complex tasks.
For both, the presentation must have insidious onset and gradual progression, with at least two cognitive domains affected and clear evidence of decline in memory and learning, alongside meeting criteria for either probable (clear genetic evidence or all of the typical clinical picture present with no evidence of mixed etiology) or possible Alzheimer’s disease, depending on how clearly the clinical picture and any available evidence point specifically to this cause rather than another.
Differential diagnosis requires distinguishing this from normal age-related cognitive change, which doesn’t involve the same degree or specific pattern of decline, and from other causes of major or mild neurocognitive disorder, particularly vascular, Lewy body, and frontotemporal causes, each with somewhat distinct clinical patterns and progression. A thorough evaluation, including cognitive testing, brain imaging, and consideration of biomarkers where available, supports accurate diagnosis and distinguishing Alzheimer’s disease from these other, sometimes overlapping, causes.
Treatment for Neurocognitive Disorder due to Alzheimer’s Disease combines medication, supportive care, and increasingly, disease-modifying approaches targeting the underlying pathology directly.
Cholinesterase inhibitors
Medications including donepezil, rivastigmine, and galantamine support cognitive function by increasing availability of a neurotransmitter important for memory and learning, generally producing modest, temporary benefit rather than reversing or stopping the underlying disease process.
Memantine
Used particularly in moderate to severe stages, memantine works through a different mechanism, regulating glutamate activity, and is sometimes used alongside a cholinesterase inhibitor.
Disease-modifying monoclonal antibody therapies
Newer medications targeting amyloid plaques directly, representing a genuinely significant shift toward addressing the underlying disease process rather than only managing symptoms, have shown modest slowing of decline in clinical trials, though their use involves careful consideration of benefits, risks (including specific monitoring requirements), and appropriate candidacy.
Addressing behavioral and psychological symptoms
Non-pharmacological approaches are generally preferred first-line for managing behavioral symptoms like agitation or anxiety, with medication reserved for situations where these approaches aren’t sufficient and safety or significant distress is a concern.
Supportive care and planning
Structured routines, cognitive and physical engagement, caregiver education and support, and early planning for future care needs and legal/financial decisions are essential components of comprehensive care, particularly given the progressive nature of this condition.
Seek evaluation promptly if you or a loved one notices a genuine change in memory or thinking, rather than assuming it’s simply normal aging. Early diagnosis supports better planning and access to treatments that may have more benefit earlier in the disease course.
Build structure and routine into daily life. Predictable schedules and environments reduce the cognitive demand of navigating uncertainty and support continued functioning for longer.
Stay engaged in cognitively and socially stimulating activities for as long as possible. While this won’t stop the underlying disease process, ongoing engagement supports quality of life and may help maintain functioning somewhat longer.
If you’re a caregiver, seek your own support early rather than waiting until you’re overwhelmed. Caregiver support groups, respite care, and professional guidance can make an enormous difference in sustaining your own wellbeing through what’s often a long caregiving journey.
Have conversations about future care preferences and legal/financial planning while the person can still meaningfully participate. Addressing this earlier, even though it’s difficult, generally leads to decisions that better reflect the person’s actual wishes.
The outlook for Neurocognitive Disorder due to Alzheimer’s Disease involves progressive decline over time, though the pace varies considerably between individuals, sometimes spanning many years from mild symptoms to more advanced stages.
Current medications provide modest symptomatic benefit and, with newer disease-modifying therapies, some slowing of decline for appropriately selected patients, though none currently halt or reverse the underlying disease process entirely.
Mild Neurocognitive Disorder doesn’t always progress to Major NCD within a given timeframe, and the pace of any progression varies considerably, though for Alzheimer’s disease specifically, progression over time is the expected, typical course rather than the exception.
Quality of life can be meaningfully supported throughout the course of the illness through appropriate medical care, structured routines, social engagement, and comprehensive caregiver support, even as the underlying cognitive decline itself continues.
Seek evaluation if you or a loved one notices persistent difficulty learning new information or other genuine changes in thinking that represent a clear change from previous functioning.
Seek comprehensive evaluation including cognitive testing and appropriate imaging, given how important accurate diagnosis is for treatment planning and distinguishing Alzheimer’s disease from other potential causes of cognitive change.
Seek caregiver support resources proactively if you’re caring for someone with this condition, given how demanding and long this caregiving journey can be, and how much earlier support tends to help sustain both the caregiver’s and patient’s wellbeing.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
The key distinction is the degree of impact on independent functioning. Mild Neurocognitive Disorder involves a genuine, measurable decline in cognition from a person’s previous baseline, but the person can still manage independent daily activities, sometimes with extra effort or compensatory strategies. Major Neurocognitive Disorder involves decline severe enough that assistance is needed with everyday activities like managing finances or medications. Many people progress from mild to major over time, though the pace varies considerably between individuals.
Some decline in processing speed and occasional word-finding difficulty is a typical, expected part of aging. Alzheimer’s disease involves a more specific, measurable pattern of decline, particularly a distinctive difficulty learning and retaining new information while memories from further in the past remain relatively preserved, representing a genuine change from the person’s own previous baseline rather than normal age-related variation.
Not currently. Available treatments, including cholinesterase inhibitors, memantine, and newer disease-modifying therapies targeting amyloid plaques, provide modest symptomatic benefit and, for some newer treatments, some slowing of decline, but none currently stop or reverse the underlying disease process entirely. Treatment focuses on supporting cognitive function, managing symptoms, and maintaining quality of life for as long as possible throughout the course of the illness.
While age and genetic factors like the APOE-e4 variant can’t be changed, addressing cardiovascular risk factors, including blood pressure, diabetes, and cholesterol, alongside maintaining cognitive and social engagement throughout life, are associated with somewhat reduced risk in research. These factors don’t guarantee prevention, but they represent meaningful, modifiable steps connected to overall brain health and may help delay or reduce risk to some degree.
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021). Alzheimer disease. Nature Reviews Disease Primers, 7, 33. PubMed
2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 20(5), 3708–3821. PubMed
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., … Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413–446. PubMed
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9–21. PubMed
Petersen, R. C. (2016). Mild cognitive impairment. Continuum (Minneapolis, Minn.), 22(2 Dementia), 404–418. PubMed
